Is magnesium sulfate by the intrathecal route efficient and safe?
| Autor: | M. S. Mebazaa, M.F. James, Taher Mestiri, N. Frikha, K Moncer, Sonia Ouerghi, M.S. Ben Ammar |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Analgesics
Magnesium business.industry medicine.medical_treatment Antagonist chemistry.chemical_element Intrathecal route General Medicine Receptors N-Methyl-D-Aspartate Magnesium Sulfate Anesthesiology and Pain Medicine Nociception chemistry Anesthesia medicine Morphine Animals Humans NMDA receptor Adverse effect business Adjuvant Injections Spinal medicine.drug |
| Zdroj: | Annales Françaises d'Anesthésie et de Réanimation. 30:47-50 |
| ISSN: | 0750-7658 |
| DOI: | 10.1016/j.annfar.2010.12.005 |
| Popis: | The polypharmacological approach to the treatment of postoperative pain has become routine in an attempt to minimize the adverse side effects of opioids. Magnesium sulphate is a noncompetitive antagonist of the N-methyl-d-aspartate (NMDA) receptor and thus can modify nociceptive modulation. Intravenous administration of magnesium sulphate can improve postoperative analgesia and decrease the requirement for postoperative opiates, but the effects are inconsistent and have not been reliably accompanied by a reduction in the incidence of morphine-related adverse events. Several studies have shown that the administration of magnesium by the intrathecal route is safe and, in combination with opiates, extends the effect of spinal anaesthesia in both animal and human studies. The analysis of these studies justifies further investigation of the use of magnesium sulphate by the intrathecal route. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect